Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that its Symphony(TM) tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
The article can be read at http://www.scientificamerican.com/article.cfm?id=wireless-blood-glucose-diabet es.
"Scientific American is one of the best known scientific trade journals and this article significantly raises the visibility of our Symphony tCGM System and the Prelude SkinPrep System for transdermal drug delivery within the scientific community and with the general public, including potential investors," commented Patrick T. Mooney, M.D., CEO and Chairman of the Board of Echo Therapeutics. "Prelude incorporates our patented skin permeation control feedback technology with a wireless, hand-held device. It is used to prepare a small area of the skin for the non-invasive biosensor and monitoring components of our Symphony tCGM System or for transdermal drug delivery. To date, we have had six consecutive positive pilot studies in glucose monitoring and our next generation skin preparation device incorporates substantial improvements beyond the prototype used in early studies. It represents one of the most important milestone events in the company's history and we anticipate that initial critical care and hospital market opportunities are greater than $1 billion. We welcome the exposure that the Scientific American article provides to our products, the hope it may give to diabetics and potential critical care users, and the progress we are making toward reaching our goals."
About Nature Publishing Group
Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.
Scientific American is at the heart of NPG's newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, Scientific American is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 16 local language editions around the world it reaches over 3 million consumers and scientists. Other titles include Scientific American Mind and Spektrum der Wissenschaft in Germany.
Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System ("Symphony") and Prelude SkinPrep System ("Prelude"), the failure of future development and preliminary marketing efforts related to Symphony and Prelude, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including Symphony and Prelude, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to Symphony and Prelude. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information: Patrick T. Mooney, M.D. Jeffrey Stanlis Chairman and Chief Executive Officer Partner, Hayden IR (508) 530-0329 (602) 476-1821
First Call Analyst:
Echo Therapeutics, Inc.
CONTACT: Patrick T. Mooney, M.D., Chairman and Chief Executive Officerof Echo Therapeutics, Inc., +1-508-530-0329, or Jeffrey Stanlis, Partner,Hayden IR, +1-602-476-1821, for Echo Therapeutics, Inc.